AN2 Therapeutics, Inc.
ANTX
$1.25
-$0.04-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.07M | 14.75M | 15.02M | 14.35M | 14.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.55M | 64.76M | 71.17M | 71.89M | 69.64M |
| Operating Income | -54.55M | -64.76M | -71.17M | -71.89M | -69.64M |
| Income Before Tax | -51.32M | -60.70M | -64.66M | -66.03M | -64.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.32 | -60.70 | -64.66 | -66.03 | -64.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.32M | -60.70M | -64.66M | -66.03M | -64.73M |
| EBIT | -54.55M | -64.76M | -71.17M | -71.89M | -69.64M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.72 | -2.04 | -2.26 | -2.59 | -2.82 |
| Normalized Basic EPS | -1.03 | -1.23 | -1.41 | -1.62 | -1.76 |
| EPS Diluted | -1.72 | -2.04 | -2.26 | -2.59 | -2.82 |
| Normalized Diluted EPS | -1.03 | -1.23 | -1.41 | -1.62 | -1.76 |
| Average Basic Shares Outstanding | 119.31M | 119.16M | 114.97M | 104.64M | 94.26M |
| Average Diluted Shares Outstanding | 119.31M | 119.16M | 114.97M | 104.64M | 94.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |